Literature DB >> 30895704

Glioma grading using a machine-learning framework based on optimized features obtained from T1 perfusion MRI and volumes of tumor components.

Anirban Sengupta1, Anandh K Ramaniharan2, Rakesh K Gupta3, Sumeet Agarwal4, Anup Singh1,5.   

Abstract

BACKGROUND: Glioma grading between intermediate grades (Grade II vs. III and Grade III vs. IV) as well as multiclass grades (Grade II vs. III vs. IV) is challenging and needs to be addressed.
PURPOSE: To develop an artificial intelligence-based methodology for glioma grading using T1 perfusion parameters and volume of tumor components, and validate the efficacy of the methodology by grading on a cohort of glioma patients. STUDY TYPE: Retrospective. POPULATION: The development set consisted of 53 glioma patients and validation consisted of 13 glioma patients. FIELD STRENGTH/SEQUENCE: Conventional MRI images (2D T1 -W, dual PD-T2 -W, and 3D FLAIR) and 3D T1 perfusion MRI data obtained at 3 T. ASSESSMENT: Enhancing and nonenhancing components of glioma were segmented out and combined to form the region of interest (ROI) for glioma grading. Prominent vessels were removed from the selected ROI. Different T1 perfusion parameters from the ROI were combined with volume of tumor components to form the feature set for glioma grading. Optimization was carried out for selection of the statistic of the T1 perfusion parameters and the features to be used for glioma grading using sequential feature selection and random forest-based feature selection method. An optimized support vector machine (SVM) classifier was used for glioma grading. STATISTICAL TESTS: Mean ± SD, analysis of variance (ANOVA) followed by the Tukey-Kramer test, ROC analysis.
RESULTS: Classification error for Grade II vs. III was 3.7%, for Grade III vs. IV was 5.26%, and for Grade II vs. III vs. IV was 9.43% using the proposed methodology. The mean of the values above the 90th percentile value of T1 perfusion parameters provided a maximum area under the curve (AUC) for intermediate grade differentiation. Random forest obtained optimal feature set provided better grading results than other methods using the SVM classifier. DATA
CONCLUSION: It was feasible to achieve low classification error for intermediate as well as multiclass glioma grading using an SVM classifier based on optimized features obtained from T1 perfusion MRI and volumes of tumor components. LEVEL OF EVIDENCE: 4 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2019;50:1295-1306.
© 2019 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  DCE-MRI; grading of glioma; machine learning; tumor subparts

Year:  2019        PMID: 30895704     DOI: 10.1002/jmri.26704

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  16 in total

1.  Comparative evaluation of intracranial oligodendroglioma and astrocytoma of similar grades using conventional and T1-weighted DCE-MRI.

Authors:  Mamta Gupta; Abhinav Gupta; Virendra Yadav; Suhail P Parvaze; Anup Singh; Jitender Saini; Rana Patir; Sandeep Vaishya; Sunita Ahlawat; Rakesh Kumar Gupta
Journal:  Neuroradiology       Date:  2021-01-19       Impact factor: 2.804

2.  Radiomics-Based Machine Learning for Outcome Prediction in a Multicenter Phase II Study of Programmed Death-Ligand 1 Inhibition Immunotherapy for Glioblastoma.

Authors:  E George; E Flagg; K Chang; H X Bai; H J Aerts; M Vallières; D A Reardon; R Y Huang
Journal:  AJNR Am J Neuroradiol       Date:  2022-04-28       Impact factor: 3.825

3.  Volumetric Measurement of Relative CBV Using T1-Perfusion-Weighted MRI with High Temporal Resolution Compared with Traditional T2*-Perfusion-Weighted MRI in Postoperative Patients with High-Grade Gliomas.

Authors:  M Seo; K-J Ahn; Y Choi; N-Y Shin; J Jang; B-S Kim
Journal:  AJNR Am J Neuroradiol       Date:  2022-05-26       Impact factor: 4.966

4.  Identification of the potential biomarkers in patients with glioma: a weighted gene co-expression network analysis.

Authors:  Ting-Yu Chen; Yang Liu; Liang Chen; Jie Luo; Chao Zhang; Xian-Feng Shen
Journal:  Carcinogenesis       Date:  2020-07-10       Impact factor: 4.944

5.  Better efficacy in differentiating WHO grade II from III oligodendrogliomas with machine-learning than radiologist's reading from conventional T1 contrast-enhanced and fluid attenuated inversion recovery images.

Authors:  Sha-Sha Zhao; Xiu-Long Feng; Yu-Chuan Hu; Yu Han; Qiang Tian; Ying-Zhi Sun; Jie Zhang; Xiang-Wei Ge; Si-Chao Cheng; Xiu-Li Li; Li Mao; Shu-Ning Shen; Lin-Feng Yan; Guang-Bin Cui; Wen Wang
Journal:  BMC Neurol       Date:  2020-02-07       Impact factor: 2.474

6.  Functional connectivity of white matter as a biomarker of cognitive decline in Alzheimer's disease.

Authors:  Yurui Gao; Anirban Sengupta; Muwei Li; Zhongliang Zu; Baxter P Rogers; Adam W Anderson; Zhaohua Ding; John C Gore
Journal:  PLoS One       Date:  2020-10-16       Impact factor: 3.240

Review 7.  Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.

Authors:  Yan Li; Yiqi Ma; Zijun Wu; Ruoxi Xie; Fanxin Zeng; Huawei Cai; Su Lui; Bin Song; Lei Chen; Min Wu
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

8.  Predictive Role of the Apparent Diffusion Coefficient and MRI Morphologic Features on IDH Status in Patients With Diffuse Glioma: A Retrospective Cross-Sectional Study.

Authors:  Jun Zhang; Hong Peng; Yu-Lin Wang; Hua-Feng Xiao; Yuan-Yuan Cui; Xiang-Bing Bian; De-Kang Zhang; Lin Ma
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

9.  Differentiation of Low-Grade Astrocytoma From Anaplastic Astrocytoma Using Radiomics-Based Machine Learning Techniques.

Authors:  Boran Chen; Chaoyue Chen; Jian Wang; Yuen Teng; Xuelei Ma; Jianguo Xu
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

Review 10.  Applications of radiomics and machine learning for radiotherapy of malignant brain tumors.

Authors:  Martin Kocher; Maximilian I Ruge; Norbert Galldiks; Philipp Lohmann
Journal:  Strahlenther Onkol       Date:  2020-05-11       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.